Roche Pharmaceuticals, through its local representative Ebn Sina Medical, a fully owned subsidiary of Aamal Company, convened a workshop dedicated to the advancements in lymphoma treatment, specifically targeting Diffuse Large B-Cell Lymphoma (DLBCL).
The event, known as the Redefining Lymphoma Gulf Countries Annual Forum, served as a platform for knowledge exchange and collaborative discussion among leading haematology experts, a statement said.
The forum saw participation from 13 professionals, representing Qatar, Kuwait, Oman, Egypt, and the UK. The agenda centred on the most current updates in the clinical management pathways for DLBCL, a challenging haematological malignancy.
Beyond the presentation of research and therapeutic strategies, the workshop facilitated an opportunity for these experts to share their firsthand experiences in treating DLBCL patients. They delved into real-world treatment outcomes observed in their respective national healthcare systems, providing a rich tapestry of practical insights that complemented the theoretical advancements discussed.
Prof Honar Cherif, head of National Center for Cancer Care and Research in Qatar, said such events are crucial for fostering collaboration and continuous medical education.
"Pharmaceutical companies’ role in facilitating these workshops is invaluable as it brings together experts who can exchange knowledge and advance patient care in haematology."
Dr Wendy Osborne, consultant haematologist specialising in Lymphoma at Freeman Hospital, Newcastle, observed that sharing experiences and getting exposed to different practices across the world are fundamental to improving patient outcomes.
Omar Hamdy, Roche Qatar and Oman lead, stated that the forum enables Gulf healthcare professionals to share their experiences to improve patient care and create long-term lymphoma treatment strategies, aligning with Roche's core purpose.
